GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (CHIX:ZEALc) » Definitions » 3-Year FCF Growth Rate

Zealand Pharma A/S (CHIX:ZEALC) 3-Year FCF Growth Rate : 24.70% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zealand Pharma A/S 3-Year FCF Growth Rate?

Zealand Pharma A/S's Free Cash Flow per Share for the three months ended in Mar. 2024 was kr-3.69.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 24.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Zealand Pharma A/S was 32.10% per year. The lowest was -70.70% per year. And the median was -19.60% per year.


Competitive Comparison of Zealand Pharma A/S's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Zealand Pharma A/S's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's 3-Year FCF Growth Rate falls into.



Zealand Pharma A/S 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Zealand Pharma A/S  (CHIX:ZEALc) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Zealand Pharma A/S 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (CHIX:ZEALC) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (CHIX:ZEALC) Headlines

No Headlines